Comparison · NCT01107743-9d608cbe
Without Renal Dysfunction vs With Renal Dysfunction: Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Without Renal Dysfunction vs With Renal Dysfunction: Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction. Trial comparisons, record NCT01107743-9d608cbe. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01107743-9d608cbe
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.955 | 0.941 | 0.966 | wilson | |
| Risk in group 2 | 0.981 | 0.933 | 0.995 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0259 | -0.0457 | 0.0235 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.974 | 0.945 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.415 | 0.0994 | 1.73 | log | |
| Number needed to treat, for one fewer participant with the outcome on Without Renal Dysfunction than on With Renal Dysfunction | 38.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Without Renal Dysfunction | Participants without Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert. | 1,036 | 1,085 | OG000 |
| Group 2 | With Renal Dysfunction | Participants with Renal Dysfunction who took Amlodipine/Atorvastatin Combination Tablets according to Japanese Package Insert. | 102 | 104 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Risk Factors for the Proportion of Responders for Hypertension -Renal Dysfunction.
- Description
- Number of Participants with responders of Amlodipine/Atorvastatin Combination Tablets to determine whether with or without Renal Dysfunction is significant risk factor for Hypertension.
- Time frame
- 8 weeks
- Population
The efficacy analysis population basically consists of the evaluable cases with Hypertension in accordance with the separately prepared analysis plan (cases judged to have been evaluated appropriately).
Source ClinicalTrials.gov
Trial
- Title
- Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- NCT number
- NCT01107743
- Phases
- Conditions
- Hypertension, Angina Pectoris, Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Amlodipine/Atorvastatin
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Results first posted
- 2013-05-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01107743?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01107743-9d608cbe